Zejing Pharmaceuticals (688266.SH): Clinical data for ZG006 and ZG005 will be released at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting.
Zejing Pharmaceutical (688266.SH) announced that the company's independently developed new drug Alveltamig (code: ...)
Zejing Pharmaceutical (688266.SH) announced that the clinical research data and latest developments of the company's independently developed new drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) will be released at the European Society for Medical Oncology (ESMO) annual meeting from October 17 to 21, 2025. Based on the data of ZG006 monotherapy in patients with advanced SCLC and NEC, it further demonstrates that ZG006 monotherapy has outstanding and durable antitumor efficacy in patients who have failed standard treatments for SCLC or NEC, and has good tolerance and safety. In patients with advanced neuroendocrine tumors, the combination of ZG005 with chemotherapy is well tolerated and safe, showing good efficacy, supporting further clinical research.
Related Articles

New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?

Guosen: The final mindset of asset trend convergence.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


